|
Factors
|
Number of patients (%)
|
Clinical response
|
Pathological response
|
|---|
| | |
Stable disease + progressive disease
|
Partial response + complete response
|
P
|
Complete pathological response
|
Incomplete pathological response
|
P
|
|---|
|
Age
|
|
45 years
|
34 (30%)
|
10
|
24
|
0.975
|
3
|
31
|
0.450
|
|
≥45 years
|
79 (70%)
|
23
|
56
| |
11
|
68
| |
|
Menopausal status
|
|
Postmenopausal
|
69 (61%)
|
20
|
49
|
0.949
|
7
|
62
|
0.364
|
|
Premenopausal
|
44 (39%)
|
13
|
31
| |
7
|
37
| |
|
Regimen
|
|
CEF
|
55 (49%)
|
15
|
40
|
0.660
|
9
|
46
|
0.212
|
|
NE
|
58 (51%)
|
18
|
40
| |
5
|
53
| |
|
Tumor size
|
|
≤5 cm
|
46 (41%)
|
21
|
25
|
0.001
|
4
|
42
|
0.323
|
|
>5 cm
|
67 (59%)
|
12
|
55
| |
10
|
57
| |
|
Lymph node status
|
|
0
|
43 (38%)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
1 to 3
|
31 (27%)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
4 to 9
|
25 (22%)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
≥10
|
14 (13%)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Pre-estrogen receptor
|
|
Negative
|
78 (69%)
|
21
|
57
|
0.426
|
10
|
68
|
0.835
|
|
Positive
|
35 (31%)
|
12
|
23
| |
4
|
31
| |
|
Pre-progesterone receptor
|
|
Negative
|
83 (73%)
|
24
|
59
|
0.911
|
9
|
74
|
0.518
|
|
Positive
|
30 (27%)
|
9
|
21
| |
5
|
25
| |
|
Pre-pMAPK
|
|
Negative
|
34 (30%)
|
13
|
21
|
0.166
|
8
|
26
|
0.855
|
|
Positive
|
79 (70%)
|
20
|
59
| |
6
|
73
| |
|
Pre-pAKT
|
|
Negative
|
30 (27%)
|
14
|
16
|
0.014
|
4
|
26
|
0.855
|
|
Positive
|
83 (73%)
|
19
|
64
| |
10
|
73
| |
|
Pre-PTEN
|
|
Negative
|
40 (35%)
|
13
|
27
|
0.568
|
5
|
35
|
0.979
|
|
Positive
|
73 (65%)
|
20
|
53
| |
9
|
64
| |
|
Pre-P27
|
|
Negative
|
35 (31%)
|
15
|
20
|
0.432
|
5
|
40
|
0.737
|
|
Positive
|
68 (69%)
|
18
|
50
| |
9
|
59
| |
|
Pre-IGF-1R
|
|
Negative
|
47 (42%)
|
12
|
35
|
0.469
|
5
|
42
|
0.634
|
|
Positive
|
66 (58%)
|
21
|
45
| |
9
|
57
| |
|
Pre-cyclinD1
|
|
Negative
|
42 (37%)
|
14
|
28
|
0.458
|
4
|
38
|
0.477
|
|
Positive
|
71 (63%)
|
19
|
52
| |
10
|
61
| |
|
Pre-Ki67
|
|
Negative
|
43 (38%)
|
15
|
28
|
0.298
|
2
|
41
|
0.076
|
|
Positive
|
70 (62%)
|
18
|
52
| |
12
|
58
| |
- IGF-1R, insulin-like growth factor 1 receptor; pAKT, phosphorylated AkT; pMAPK, phosphorylated mitogen-activated protein kinase.
